IDH mutation can catalyze the conversion of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG) (Figure 1), and studies have found that the level of 2-HG in cancer patients is higher than that in normal or non-mutated cancer patients (6–8). This evidence concerns the gene IDH1 and cancer.